{
  "thread": {
    "uuid": "06c9eecc7ad3dfb492d26a0a44a0e788bd481ff5",
    "url": "https://investorshangout.com/shattuck-labs-set-to-showcase-innovations-at-healthcare-conference-257732-",
    "site_full": "investorshangout.com",
    "site": "investorshangout.com",
    "site_section": "https://investorshangout.com/recovery",
    "site_categories": [
      "stocks",
      "finance",
      "options"
    ],
    "section_title": "Password Recovery",
    "site_title": "Investors Hangout – Stock Message Boards, Latest Stock Quotes & Financial News",
    "title": "Shattuck Labs Set to Showcase Innovations at Healthcare Conference",
    "title_full": "Shattuck Labs Set to Showcase Innovations at Healthcare Conference",
    "published": "2025-04-03T00:18:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "US",
    "main_image": "https://investorshangout.com/images/blog/ihnews-Shattuck%20Labs%20Set%20to%20Showcase%20Innovations%20at%20Healthcare%20Conference.jpg",
    "performance_score": 0,
    "domain_rank": 125397,
    "domain_rank_updated": "2025-04-01T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "06c9eecc7ad3dfb492d26a0a44a0e788bd481ff5",
  "url": "https://investorshangout.com/shattuck-labs-set-to-showcase-innovations-at-healthcare-conference-257732-",
  "ord_in_thread": 0,
  "author": "Henry Turner",
  "published": "2025-04-03T00:18:00.000+03:00",
  "title": "Shattuck Labs Set to Showcase Innovations at Healthcare Conference",
  "text": "Shattuck Labs Set to Showcase Innovations at Healthcare Conference\nHenry TurnerUpdated: 04-02-2025 05:18 PM\nShattuck Labs to Present at the Virtual Healthcare Conference\nAUSTIN, TX and DURHAM, NC — Shattuck Labs, Inc. (NASDAQ: STTK), a leader in biotechnology, is excited to announce its participation in the 24th Annual Needham Virtual Healthcare Conference. The event is set to take place from April 7 to April 10, and Shattuck Labs will host presentations and one-on-one meetings during this important industry gathering.\nEvent Details and Presentation Schedule\nDuring the conference, Shattuck's Chief Executive Officer, Dr. Taylor Schreiber, will deliver a presentation on April 9 at 3:00 PM EDT. This will provide an excellent opportunity for attendees to gain insights into the company's innovative work in developing novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors.\nAccessing the Conference\nFor those unable to attend live, a live webcast will be available on Shattuck’s official website in the Events and Presentations section. A replay of the presentation will also be archived for one month following the event, making it convenient for interested parties to catch up on the latest developments.\nInsights into Shattuck's Lead Program: SL-325\nOne of the key focuses of Shattuck Labs is SL-325, a promising candidate that acts as a blocking antibody for Death Receptor 3 (DR3). This innovative therapy aims for a complete blockade of the DR3/TL1A pathway, which has been clinically validated. Preclinical studies suggest that SL-325 exhibits high affinity binding and offers enhanced activity compared to existing TL1A antibodies.\nAdvancement and Development Timeline\nRecently, SL-325 completed a Good Laboratory Practice (GLP) toxicology study in non-human primates. Shattuck Labs anticipates filing an Investigational New Drug (IND) application in the third quarter of 2025, marking a significant step forward in its development timeline.\nAbout Shattuck Labs, Inc.\nFounded with a mission to address inflammatory and immune-mediated diseases, Shattuck Labs, Inc. (NASDAQ: STTK) is at the forefront of biotechnology, specializing in groundbreaking treatments. The company’s expertise in protein engineering fuels its development of SL-325, aiming to provide more effective solutions for patients suffering from inflammatory bowel disease (IBD) and related conditions.\nCompany Presence and Future Directions\nShattuck Labs operates from both Austin, Texas, and Durham, North Carolina, while continuously exploring future opportunities to expand its innovative pipeline. As the company focuses on driving the clinical translation of its research, it remains committed to enhancing patient care and treatment options.\nFrequently Asked Questions\nWhat does Shattuck Labs do?\nShattuck Labs focuses on developing novel therapeutics targeting immune-related diseases, particularly through its lead program SL-325.\nWhen will SL-325 be available for clinical use?\nThe IND filing for SL-325 is expected in the third quarter of 2025, moving it closer to clinical trials.\nWho will present at the Needham Virtual Healthcare Conference?\nDr. Taylor Schreiber, the Chief Executive Officer of Shattuck Labs, will be presenting.\nWhere can I watch the conference live?\nA live webcast will be available on Shattuck’s official website during the conference.\nWhat is the significance of the DR3/TL1A pathway?\nThe DR3/TL1A pathway plays a pivotal role in inflammatory responses, making it a critical target for therapeutic exploration.\nAbout The Author\nContact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.\nAbout Investors Hangout\nInvestors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/\nThe content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "positive",
  "categories": [
    "Health",
    "Science and Technology"
  ],
  "topics": [
    "Health->health organisation",
    "Health->health care approach",
    "Health->medical profession",
    "Science and Technology->biomedical science",
    "Science and Technology->scientific innovation",
    "Science and Technology->scientific research"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": false,
  "webz_reporter": false,
  "external_links": [],
  "entities": {
    "persons": [
      {
        "name": "GLP",
        "sentiment": "positive"
      },
      {
        "name": "Shattuck Labs Set",
        "sentiment": "neutral"
      },
      {
        "name": "Henry TurnerUpdated",
        "sentiment": "neutral"
      },
      {
        "name": "Taylor Schreiber",
        "sentiment": "neutral"
      }
    ],
    "locations": [
      {
        "name": "AUSTIN",
        "sentiment": "neutral"
      },
      {
        "name": "TX",
        "sentiment": "neutral"
      },
      {
        "name": "DURHAM",
        "sentiment": "neutral"
      },
      {
        "name": "NC",
        "sentiment": "neutral"
      },
      {
        "name": "Texas",
        "sentiment": "neutral"
      },
      {
        "name": "North Carolina",
        "sentiment": "neutral"
      }
    ],
    "organizations": [
      {
        "name": "Advancement and Development Timeline",
        "sentiment": "positive",
        "tickers": []
      },
      {
        "name": "IBD",
        "sentiment": "positive",
        "tickers": []
      },
      {
        "name": "Showcase Innovations at Healthcare Conference",
        "sentiment": "neutral",
        "tickers": []
      },
      {
        "name": "the Virtual Healthcare Conference",
        "sentiment": "neutral",
        "tickers": []
      },
      {
        "name": "Shattuck Labs, Inc.",
        "sentiment": "neutral",
        "tickers": []
      },
      {
        "name": "STTK",
        "sentiment": "neutral",
        "tickers": []
      },
      {
        "name": "Death Receptor 3",
        "sentiment": "neutral",
        "tickers": []
      },
      {
        "name": "Investigational New Drug (IND",
        "sentiment": "neutral",
        "tickers": []
      },
      {
        "name": "the Needham Virtual Healthcare Conference",
        "sentiment": "neutral",
        "tickers": []
      },
      {
        "name": "ATTN",
        "sentiment": "neutral",
        "tickers": []
      }
    ]
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "bias": null
  },
  "rating": null,
  "crawled": "2025-04-03T00:30:09.744+03:00",
  "updated": "2025-04-03T00:30:09.744+03:00"
}